Method for administering omega-conopeptide
The present invention is directed to a method of producing analgesia in a mammalian subject. The method includes administering to the subject an omega conopeptide, preferably ziconotide, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl l, buprenorphine, and sufentanil, or its pharmaceutically acceptable salts thereof, wherein the ω-conopeptide retains its potency and is physically and chemically compatible with the analgesic compound. A preferred route of administration is intrathecal administration, particularly continuous intrathecal infusion. The present invention is also directed to a pharmaceutical formulation comprising an omega conopeptide, preferably ziconotide, an antioxidant, in combination with an analgesic selected from the group consisting of morphine, bupivacaine, clonidine, hydromorphone, baclofen, fentanyl, buprenorphine, and sufentanil.
1. A method for treating severe chronic pain in a human patient, comprising:
administering ziconotide to a human patient suffering from severe chronic pain by continuous intrathecal infusion with a dose starting at 0.6 μg/day, titrating upward by up to 2.4 μg/day per week, and up to a maximum of 7.2 μg/day or until improved analgesia is obtained.
2. The method according to claim 1 , wherein the patient is treated for 14-35 days.
3. The method according to claim 1 , The method according to claim 1 , wherein the cumulative dose of the ziconotide is 8.8-118.6 μg.
4. The method according to claim 1 , wherein said ziconotide is administered in a pharmaceutical composition comprising an antioxidant.
5. The method according to claim 4 , wherein said antioxidant is methionine.
6. The method according to claim 4 , wherein said pharmaceutical formulation has pH between 4 and 4.5.
7. The method according to claim 4 , wherein said ziconotide is supplied in a single dose vial.
8. The method according to claim 7 , wherein said ziconotide has a concentration of 100 μg/mL in the vial.
9. The method according to claim 4 , wherein the ziconotide is administered via a drug dispensing implantable pump.
10. The method according to claim 1 , wherein the human patient is being administered a therapeutically effective amount of an opioid.